 phase II evaluation menogaril cisplatin-refractory advanced ovarian carcinoma collaborative trial North Central Cancer Treatment Group Mayo Clinic women advanced recurrent epithelial ovarian carcinoma prior chemotherapy platinum-based regimen menogaril weeks Phase II trial Partial responses measurable disease patients nonmeasurable evaluable patients overall objective response rate confidence interval Median time progression patients months median survival months Toxicities acceptable leukopenia gastrointestinal toxicity Twenty-nine percent patients venous irritation painful phlebitis intravenous injection site Menogaril protocol modest antineoplastic activity ovarian carcinoma patients responses short duration survival advantage menogaril treatment